Better efficacy of a 12-month interferon Alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial

Hepatology

Volumn 28, Issue 6, 1998, Pages 1680-1686

  Payen, Jean Louis ^a,c   Izopet, Jacques ^b   Galindo Migeot, Virginie ^c   Lauwers Cances, Valérie ^c   Zarski, Jean Pierre ^d   Seigneurin, Jean Marie ^e   Dussaix, Elizabeth ^f   Voigt, Jean Jacques ^g   Selves, Janick ^c   Barange, Karl ^a   Puel, Jacqueline ^b   Pascal, Jean Pierre ^a  

^a Services d'Hépato Gastroentérologie   (France)

^b Laboratoire de Virologie   (France)

^c CHU PURPAN   (France)

^d Dept d'Hépato Gastroenterol ^*  (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f Service de Virologie CHU   (France)

^g Serv d'Anat Pathologique Ctr CR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 17344364796     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280631     Document Type: Article

References (29)

1. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant Interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
3. Di Bisceglie AM, Martin P, Kassianides C, Lisker Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant Interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
4. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995;332:1457-1462.
5. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, et al. L'interféron alpha recombinant chez les patients atteints d'hépatite chronique non-A non-B. Essai contrôlé randomisé multicentrique en France. Médecine et Chirurgie Digestives 1991;20:41-44.
6. Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. HEPATOLOGY 1997;26(Suppl 1):83S-88S.
7. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. HEPATOLOGY 1997;26(Suppl 1):137S-142S.
8. Rabinovitz M, Block G, Finkelstein SD. Alpha-interferon retreatment of patients with chronic hepatitis C. Am J Gastroenterol 1996;91:1523-1526.
9. Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, Kiriyama S, et al. Retreatment of chronic hepatitis C with interferon [Comments]. Am J Gastroenterol 1994;89:1453-1457.
10. Weiland O, Zhang YY, Widell A. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993;25:25-30.
11. Marriott E, Quiroga JA, Carreno V. Retreatment of chronic hepatitis C with interferon-alpha. J Infect Dis 1992;166:1200-1201.
12. Marcellin P, Boyer N, Pouteau M, Benhamou JP, Erlinger S. Retreatment with interferon-alpha of chronic hepatitis C virus infection. Lancet 1994;344:690-691.
13. Gerken G, Teuber G, Goergen B, Meyer Zum Büschenfelde KH. Interferon alpha retreatment in chronic hepatitis C. J Hepatol 1995;22(Suppl 1):118-121.
14. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, Bernardinello E, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;113:1654-1659.
15. Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, et al. Re-treatment with interferon alfa of patients with chronic hepatitis C. HEPATOLOGY 1998;27:1144-1148.
16. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, et al. Re-treatment of chronic hepatitis C with consensus interferon. HEPATOLOGY 1998;27:1136-1143.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
18. Knodell RG, Isahak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
19. Bedossa P, the French METAVIR Cooperative Study Group. Intraobservater and interobservater variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
20. Simmonds P, Alberti! A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. HEPATOLOGY 1994;19:1321-1324.
21. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski J P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
22. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman M, et al. Retreatment of relapse after interferon therapy for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone. HEPATOLOGY 1997;26:247A.
23. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1995;330:143.
24. Izopet J, Payen JL, Alric L, Sandres K, Charlet JP, Vinel JP, Duffaut M, et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998;54:86-91.
25. Lindsay KL, Davis GL, Schiff ER. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. HEPATOLOGY 1996;24:1034-1040.
26. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
27. Tsubota A, Chayama K, Ikeda K. Factors predicitive of response to interferon-α therapy in hepatitis C infection. HEPATOLOGY 1994;19:1088-1094.
28. d'Aquino M, Tempesta D, Bibiani S, Vianello G, Pipan C, Belati G, Colloredo G, et al. Chronic hepatitis C: analysis of factors which influence the response to interferon therapy proven to be useful to optimize a second course [Abstract]. HEPATOLOGY 1996;24:498A.
29. Cammà C, Giunta M, Libea C, Pagliaro L. The effect of interferon on the liver in chronic hepatits C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-1199.